Hepatitis C treatments
For more information about anything in this factsheet, phone
the Hepatitis Infoline on 1800 803 990 or go to
The information in this factsheet was current at 1 August 2017 and will be amended as new information
Hepatitis NSW does not want to appear to give preference or prominence to one treatment regime over
another. This factsheet relates to these hepatitis C treatment drugs (in alphabetical order):
Epclusa (sofosbuvir/velpatasvir) two drugs combined in one pill
Harvoni (sofosbuvir/ledipasvir) two drugs combined in one pill
Sovaldi-Daklinza (sofosbuvir and daclatasvir) in separate pills
Sovaldi-Ibavyr (sofosbuvir and ribavirin) in separate pills
VIEKIRA PAK (paritaprevir/ritonavir/ombitasvir and dasabuvir) in separate pills
Zepatier (elbasvir and grazoprevir) two drugs combined into one pill.
Treating doctors will advise which treatment options are suitable for individual patients, based on the
patient’s genotype, level of liver damage and treatment history. Depending on these factors, the
treatment drug Ibavyr (ribavirin) might be added to: Epclusa, VIEKIRA PAK or Zepatier.
Other new drugs for treating hepatitis C are currently in different stages of development and/or approval.
Over time, these new drugs will also likely be PBS listed and funded, and this factsheet will be amended
Success rates of the new treatments
All the above treatments achieve cure rates around 95% or more, depending on pre-treatment variables
such as the presence of cirrhosis or prior therapy. The cure rates also relate to people’s hepatitis C
Treatments and genotypes
Treating doctors will advise which treatment options are suitable for individual people. Here is a guide to
the likely treatment option by genotype:
Patients with genotype 1a or 1b, can be offered Epclusa or Harvoni or Sovaldi-Daklinza, or Zepatier
Patients with genotype 1a, can be offered Epclusa or VIEKIRA PAK-Ibavyr
Patients with genotype 1b, can be offered Epclusa or VIEKIRA PAK
Patients with genotype 2, can be offered Epclusa or Sovaldi-Ibavyr
Patients with genotype 3, can be offered Epclusa or Sovaldi-Daklinza
Patients with genotype 4, can be offered Epclusa or Zepatier
Patients with genotypes 5 or 6, can be offered Epclusa.
Other drug combinations are approved and available and some of the above options might also include
Ibavyr (ribavirin). The above combinations are the ones with best response and tolerability.